金城医药 reported revenue of ¥1.45B for the period ended 2026-06-30, +6.4% year on year. Net income was ¥0.14B, a 9.8% net margin on a 35.4% gross margin. The largest revenue line is 其他 at 33% of the total. Free cash flow for the period was ¥0.09B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.45B | +6.4% |
| Gross profit | ¥0.51B | — |
| Operating income | ¥0.17B | — |
| Net income | ¥0.14B | +214.7% |
| Gross margin | 35.4% | Net margin 9.8% |
| Revenue Q/Q | -7.1% | — |
| Segment | Revenue | Share |
|---|---|---|
| 其他 | ¥0.48B | 33.2% |
| 制剂产品 | ¥0.38B | 26.5% |
| 头孢侧链活性酯系列产品 | ¥0.32B | 21.8% |
| 生物制药及特色原料药系列产品 | ¥0.27B | 18.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.94B | 64.6% |
| R&D | ¥0.08B | 5.4% |
| SG&A | ¥0.27B | 18.9% |
| Tax & other | ¥0.03B | 2.3% |
| Item | Amount |
|---|---|
| Total assets | ¥5.11B |
| Total liabilities | ¥1.30B |
| Shareholders' equity | ¥3.81B |
| Equity / assets | 74.6% |
| Operating cash flow | ¥0.11B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.09B |
| Cash conversion (OCF / net income) | 137% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
开尔新材 ・ 方直科技 ・ 上海新阳 ・ ST美晨 ・ 冠昊生物 ・ 东宝生物 ・ 飞力达 ・ 瑞丰光电 ・ 佳云科技 ・ 瑞丰高材 ・ 迪安诊断 ・ ST天玑
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies